



State-of-the-Art Neurophysiology and Biochemistry of Brain Diseases in Europe

Guest Editors:

Prof. Dr. Rosanna Di Paola

Department of Chemical,
Biological, Pharmaceutical and
Environmental Sciences,
University of Messina, 98166
Messina, Italy

Dr. Marika Cordaro

Department of Biomedical and
Dental Sciences and
Morphofunctional Imaging,
University of Messina, 98125
Messina, Italy

Dr. Roberta Fusco

Department of Chemical,
Biological, Pharmaceutical and
Environmental Sciences,
University of Messina, 98166
Messina, Italy

Deadline for manuscript
submissions:

closed (31 May 2023)

Message from the Guest Editors

We are pleased to announce a volume dedicated to the state of the art in the biochemistry and pathophysiology of the brain.

The medical, social, and economic impact of age-related neurodegenerative diseases is immense, and is increasing rapidly as life expectancy is extended and the average age of the population shifts upward. These disorders, which include Alzheimer's disease, Parkinson's disease, prion diseases and amyotrophic lateral sclerosis, are due to the misfolding and aggregation of key brain proteins. Multiple sclerosis is another chronic neurological condition that is the subject of intensive research. All these disorders are related to perturbations in key cellular and molecular pathways, including those related to protein folding and degradation, neuronal plasticity, and inflammation. Recently, emerging and novel biomarkers have been identified and validated, and have had a huge impact on patients' outcomes and improved the treatment landscape. We cordially invite experts in the field to submit original research or review articles pertaining to this important and fast-progressing field of biomedicine.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research
Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA

2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

High Visibility: indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [CAPUS / SciFinder](#), and [other databases](#).

Journal Rank: JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Biomedicines Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
[X@Biomed_MDPI](#)